Compliance with biologic therapies for rheumatoid arthritis: Do patient out‐of‐pocket payments matter?

Abstract

Most patients pay less than $20/week for biologics, but a small number have high OOP expenses, associated with lower medication compliance. The adverse impact of high OOP costs on adherence, persistence, and outcomes must be considered when making decisions about increasing copayments.